Please login to the form below

Not currently logged in

Merck & Co to buy IO specialists Immune Design for $300m

US giant looks to next generation technology


Immunotherapy leader Merck & Co/MSD is to acquire a vaccine specialist firm Immune Design for $300m

The move is aimed at helping the pharma giant consolidate its dominance in the field of immunotherapy (IO), where its checkpoint inhibitor Keytruda leads with annual sales of $7bn in 2018.

The race is now on to find the next generation IO mechanism which could unlock greater benefits for patients across a range of diseases, and not just cancer.

Big pharma, biotech and academia are zeroing in on a range of immune system mechanisms which could prove crucial to fighting diverse diseases.

The acquisition is significant, not least because it has been some time since Merck & Co. last went shopping for a new bolt-on technology.

Immune Design is a late-stage immunotherapy company using its own next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies, GLAAS and ZVex, are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic immune cells to fight cancer and other chronic diseases.

Merck & Co. have moved in to buy the Seattle-based company at an opportunistic time, as the firm suffered setbacks to its in-house development pipeline in October last year. The big pharma company's head of R&D, Roger Perlmutter has clearly identified some potential synergies between Immune Design's capabilities and its own pipeline, and has swooped to acquire the firm.

Roger Perlmutter

Merck's R&D chief Roger Perlmutter

“Scientists at Immune Design have established a unique portfolio of approaches to cancer immunisation and adjuvant systems designed to enhance the ability of a vaccine to protect against infection, which could meaningfully improve vaccine development," said Dr. Roger Perlmutter. “This acquisition builds upon Merck’s industry-leading programmes that harness the power of the immune system to prevent and treat disease.”

“Merck has a rich history of discovery and innovation and a strong track record of developing meaningful therapeutics and vaccines,” said Dr. Carlos Paya, president and chief executive officer, Immune Design. “We believe this agreement creates shareholder value by positioning our technologies and capabilities for long-term success with a leading, research-driven biopharmaceutical company.”

Article by
Andrew McConaghie

21st February 2019

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...